CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival

Modern Pathology

Volumn 23, Issue 4, 2010, Pages 531-538

  Krasinskas, Alyssa M ^a   Bartlett, David L ^a   Cieply, Kathleen ^a   Dacic, Sanja ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

CDKN2A; Fluorescence in situ hybridization; Immunohistochemistry; MTAP; P16; Peritoneal mesothelioma

Indexed keywords

ASBESTOS; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MTAP GENE; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 77950518087     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.186     Document Type: Article

References (35)

1. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
2. Hesdorffer ME, Chabot J, DeRosa C, et al. Peritoneal mesothelioma. Curr Treat Options Oncol 2008;9: 180-190.
3. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-112. (Pubitemid 38082517)
4. Browne K, Smither WJ. Asbestos-related mesothelio-ma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983;40:145-152. (Pubitemid 13120206)
5. Antman KH, Pomfret EA, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983;1:386-391. (Pubitemid 14181198)
6. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008;98:268-272.
7. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6-12.
8. Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:686-691. (Pubitemid 44063999)
9. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytor-eductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229-237. (Pubitemid 43157418)
10. Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007;14:41-49. (Pubitemid 44954269)
11. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinoma-tosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009;7:5.
12. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567.
13. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothe-lioma. Cancer Genet Cytogenet 2006;170:9-15. (Pubitemid 44349011)
14. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-747. (Pubitemid 351744840)
15. Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioa-denosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-2113.
16. Xio S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11: 511-515.
17. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 2008;453:627-635.
18. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551. (Pubitemid 2158337)
19. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998;75:649-653.
20. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003;99:51-56. (Pubitemid 36267967)
21. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005;49(Suppl 1): S95-S98. (Pubitemid 40798856)
22. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: over-expression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006;66:2970-2979.
23. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005;11:3303-3308. (Pubitemid 40627879)
24. Destro A, Ceresoli GL, Baryshnikova E, et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2008;59:369-376. (Pubitemid 351335109)
25. Kobayashi N, Toyooka S, Yanai H, et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008;62:120-125.
26. Wong L, Zhou J, Anderson D, et al. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-136. (Pubitemid 35154376)
27. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15:754-763.
28. Yan TD, Popa E, Brun EA, et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006;93:1536-1542. (Pubitemid 44893657)
29. Della Ragione F, Russo G, Oliva A, et al. 5-Deoxy-5-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene 1995;10:827-833.
30. Stadler WM, Olopade OI. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 1996;24:239-244.
31. Zhang H, Chen ZH, Savarese TM. Codeletion of the genes for p16INK4, methylthioadenosine phosphory-lase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet 1996;86:22-28. (Pubitemid 26079084)
32. Kindler HL, Burris III HA, Sandler AB, et al. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2009;27:75-81.
33. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 2009;4:e5735.
34. Goldblum J, Hart WR. Localized and diffuse mesothe-liomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multi-cystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 1995;19:1124-1137.
35. Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002;94:378-385.